newsfilter
← Latest News
PR Newswire·

Emmaus Life Sciences Acquires Key Intellectual Property Rights to Novel IRAK4 Inhibitor From Kainos Medicine

TORRANCE, Calif., Oct. 12, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX:EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced the signing of an agreement with Kainos